Mark Iwicki has more than 25 years of experience leading all aspects of R&D and commercialization in the biopharmaceutical industry. He is the Chairman and CEO of Kala Pharmaceuticals, and was previously the CEO of Civitas Therapeutics, which was acquired by Acorda Therapeutics.
Prior to Civitas, Mark served as the President and Chief Executive Officer of Blend Therapeutics, President and Chief Executive Officer of Sunovion Pharmaceuticals, and President and Chief Operating Officer at Sepracor, which was acquired in 2009. During his previous tenure at Novartis, Mark served as Business Unit Head and managed the Cardiovascular, Diabetes, Arthritis, Bone, Gastrointestinal, HRT, Infectious Diseases, and Urology therapeutic areas. Preceding these roles, Mark held management positions at Merck and Astra Merck.
Mark serves on the boards of Kala Pharmaceuticals, Aimmune Therapeutics, Merus, Nimbus Therapeutics, and Pulmatrix. Mark holds a BS from Ball State University and an MBA from Loyola University.